π Premium: Vaccine makers looking to spend, spend, spend after massive Covid windfall
Vaccine maker Pfizer’s share price has more than doubled since the pandemic began, and the company’s revenue is set to pass a new barrier of $100bn this year.
Vaccine maker Pfizer’s share price has more than doubled since the pandemic began, and the company’s revenue is set to pass a new barrier of $100bn this year.